Alvotech (ICE:ALVO)
Iceland · Delayed Price · Currency is ISK 984.00
-41.00 (-4.00%)
At close: Oct 28, 2025
Alvotech Employees
Alvotech had 1,012 employees as of December 31, 2024. The number of employees increased by 13 or 1.30% compared to the previous year.
Employees
1,012
Change (1Y)
13
Growth (1Y)
1.30%
Revenue / Employee
67.29M ISK
Profits / Employee
7.58M ISK
Market Cap
305.35B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,012 | 13 | 1.30% |
| Dec 31, 2023 | 999 | 82 | 8.94% |
| Dec 31, 2022 | 917 | 133 | 16.96% |
| Dec 31, 2021 | 784 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Marel | 7,500 |
| Hagar | 2,699 |
| Hampiðjan | 1,947 |
| Festi | 1,352 |
| Arion banki | 822 |
| Íslandsbanki | 764 |
| Sildarvinnslan Hf. | 723 |
| Brim hf. | 694 |
Alvotech News
- 8 days ago - Alvotech Announces Changes in Global Business Development and Commercial Operations Team - GlobeNewsWire
- 8 days ago - Alvotech Announces Changes in Global Business Development and Commercial Operations Team - GlobeNewsWire
- 15 days ago - Alvotech: Promising Vertically Integrated Biosimilar Platform - Seeking Alpha
- 23 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 24 days ago - European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency - GlobeNewsWire
- 5 weeks ago - European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva® - GlobeNewsWire
- 5 weeks ago - European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva® - GlobeNewsWire
- 5 weeks ago - European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner - GlobeNewsWire